Showing results (121-130 of 172) with videos related to

Sort By:
Pageof 18
Arthritis and Rheumatism|June 16, 2001
A randomized, controlled trial of methotrexate versus placebo in early diffuse sclerodermaJ E Pope, N Bellamy, J R Seibold, et al.
The Journal of Rheumatology|March 7, 1998
Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosisJ R Seibold, P J Clements, D E Furst, et al.
Annals of the Rheumatic Diseases|May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT groupJérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
Arthritis Research & Therapy|June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are neededChristopher P Denton, Jerome Avouac, Frank Behrens, et al.
Annals of the Rheumatic Diseases|July 27, 2006
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk testM H Buch, C P Denton, D E Furst, et al.
Rheumatology (Oxford, England)|August 16, 2014
Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standardsDinesh Khanna, Daniel E Furst, Yannick Allanore, et al.
The Journal of Rheumatology|October 4, 2011
Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS)Otylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Clinical and Experimental Rheumatology|June 26, 2010
Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosisDoerte Huscher, David Pittrow, Oliver Distler, et al.
The Journal of Rheumatology|December 4, 2009
Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS groupOtylia Kowal-Bielecka, Jerome Avouac, David Pittrow, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD TrialEric L Matteson, Clive Kelly, Jörg H W Distler, et al.
Pageof 18